Mon Sep 23 22:30:44 UTC 2024: ## Veracyte Director Sells Shares, Institutional Investors Show Interest
**San Francisco, CA** – Veracyte, Inc. (NASDAQ: VCYT) saw a director, Evan/ Fa Jones, sell 5,173 shares of the company on September 19th at an average price of $35.23, totaling $182,244.79. Following the transaction, Jones now holds 34,343 shares, valued at approximately $1,209,903.89.
Veracyte’s stock price dipped slightly on Monday, closing at $34.26. While the company’s market cap sits at $2.62 billion, its P/E ratio stands at -37.05, indicating a potential growth opportunity.
Analysts remain divided on the stock’s outlook. Morgan Stanley issued an “underweight” rating with a $26 price target, while Needham & Company LLC assigned a “buy” rating with a $37 price target. The overall consensus rating from MarketBeat is “Moderate Buy,” with an average price target of $31.25.
Veracyte continues to attract interest from institutional investors. Vanguard Group Inc. increased its stake in the company by 3.7% during the first quarter, owning 7,384,871 shares worth $163,649,000. Other notable investors include Seven Eight Capital LP, Sumitomo Mitsui Trust Holdings Inc., Norges Bank, and Granahan Investment Management LLC, all making significant investments in Veracyte.
Veracyte, a diagnostics company specializing in genomic sequencing, offers a range of tests for various cancers, including thyroid, prostate, breast, and lung cancer. They also provide diagnostic tools for interstitial lung disease.
The recent director sale and continued institutional interest highlight the ongoing debate about Veracyte’s future prospects. While some analysts remain cautious, others see a potential for growth in the diagnostics sector.
First Piper 